1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Technology appraisal guidance [TA495] Published date: 20 December 2017

  • Guidance
  • Tools and resources
  • Information for the public
  • History

Documents

A list of downloadable documents created during development.

Final appraisal determination: 1

  • Final appraisal determination: 1  
  • Final appraisal determination document PDF 442.03 KB 16 November 2017  
  • Public committee slides ACM3 PDF 644.05 KB 16 November 2017  
  • Public committee slides ACM2 PDF 606.39 KB 16 November 2017  
  • Committee papers Equality Impact Assessment Form PDF 234.6 KB 16 November 2017  
  • Committee papers PDF 6.13 MB 16 November 2017  

Appraisal consultation

  • Appraisal consultation  
  • Appraisal consultation document PDF 423.65 KB 03 February 2017  
  • Committee papers PDF 24.04 MB 03 February 2017  
  • Committee papers Clinical and Cost Effectiveness Presentation Slides PDF 1.39 MB 03 February 2017  

Invitation to participate

  • Final scope PDF 114.49 KB 09 August 2016  
  • Final matrix PDF 99.98 KB 09 August 2016  
  • NICE's response to comments on the draft scope and provisional matrix PDF 215.22 KB 09 August 2016  
  • Equality impact assessment (Scoping) PDF 63.72 KB 09 August 2016  

Draft scope documents

  • Draft scope (pre-referral) PDF 132.17 KB 21 June 2016  
  • Provisional matrix (pre-referral) PDF 101.69 KB 21 June 2016